Many gene fusions have been reported in tumours and for most their role remains unknown. As fusions can be used clinically for diagnostic and prognostic purposes, and are targets for treatment, it is crucial to assess their functional implications in cancer. To investigate the role of fusions in tumor cell fitness, we developed a systematic analysis utilising RNA-sequencing data from 1,011 human cancer cell lines to functionally link 8,354 gene fusion events with genomic data, sensitivity to >350 anti-cancer drugs and CRISPR-Cas9 loss-of-fitness information. Established clinically-relevant fusions were readily identified. Overall, functional fusions were rare, including those involving cancer driver genes, suggesting that many fusions are dispensable for tumor cell fitness. Novel therapeutically actionable fusions involving RAF1 , BRD4 and ROS1 were verified in new histologies. In addition, recurrent YAP1-MAML2 fusions were identified as activators of Hippo-pathway signaling in multiple cancer types, supporting therapeutic targeting of Hippo signalling. Our approach discriminates functional fusions, identifying new drivers of carcinogenesis and fusions that could have important clinical implications. 1 Significance We identify fusions as new potential candidates for drug repurposing and drivers of carcinogenesis. These results support histology agnostic marker-driven precision cancer medicine. M ost fusions are not functional with implications for interpreting cancer fusions reported from clinical sequencing studies.
Introduction
Oncogenic gene fusions occur in solid tumours and hematologic malignancies, and are used for diagnostic purposes, patient risk stratification and for monitoring of residual disease 1 .
Critically, the chimeric protein encoded by fusions may be a tumor specific target for treatment, resulting in significant clinical benefit for patients 2, 3 . Fusions are often associated with a specific tissue histology, but can occur at a low frequency in multiple histologies. Gene fusion transcripts are composed of two independent genes formed either through structural rearrangements, transcriptional read-through of adjacent genes, or pre-mRNA splicing. The exchange of coding or regulatory sequences between genes can result in aberrant functionality of the fusion protein, and deregulation of the partner genes, including overexpression of oncogenes and decreased expression of tumor suppressor genes (TSG).
Discriminating between fusions that have a role in cancer fitness and those that do not is a major challenge with important clinical implications 4 . Deep sequencing technology together with sensitive fusion detection algorithms have led to a dramatic increase in the number of reported cancer-associated fusions 5 . Most fusion transcripts are likely the indirect consequence of genomic instability or false-positive events due to error-prone fusion calling. Previous studies have focused on the identification of fusions, or have investigated the function of specific gene fusions, for example in the setting of acute myeloid leukemia (AML) 6 . The functional role of most fusions has not been investigated.
We have generated large-scale genomic and pharmacological datasets for >1,000 human cancer cell lines as part of the Genomics of Drug Sensitivity in Cancer (GDSC) project 7, 8 .
These datasets, together with recent advances in CRISPR genetic screening technology, make it now possible to systematically assess the contribution of fusions transcripts to cancer cell fitness.
Here, we report the first comprehensive functional landscape of fusions events using RNA sequencing (RNA-seq) data for 1,011 human cancer cell lines. We investigate the functional relevance of gene fusions using differential gene expression, drug sensitivity to >350 anti-cancer compounds, and whole-genome CRISPR-Cas9 drop out screens to identify fusions required for cancer cell fitness. To our knowledge, this study is the first large-scale systematic analysis in a large collection of human cancer models to unveil the largely unexplored functional role of gene fusion.
Results

Landscape of fusion transcripts
To systematically identify gene fusions in diverse cancer types, we first analyzed RNA-seq data to define fusion transcripts in the GDSC cancer cell lines (1,034 samples from 1,011 unique cell lines) representing 41 cancer types (Fig. 1a ). RNA-seq data for 587 cell lines was obtained from the Cancer Genome Hub (CGHub) and 447 cell lines were sequenced at the 3 Sanger Institute. Fusion calling algorithms are prone to detecting false positives from sequencing artefacts and alignment ambiguities 9 . To improve the accuracy of fusion transcript calling, we used three different algorithms, deFuse, TopHat-Fusion and STAR-Fusion, across all samples [10] [11] [12] and applied stringent filtering criteria. In total, 10,514 fusion transcripts were called by more than one algorithm and taken forward for this study (Fig. 1b ). Targeted PCR of 406 putative fusion breakpoints resulted in validation rate of 71.6%. Furthermore, we compared the 23 samples with RNA-seq data from both Sanger Institute and CGHub ( Supplementary Table 1 ) and the proportion of fusions transcripts in both data sources for a given cell line was 70.4%. Some fusions have multiple transcripts in the same cell line and so we define a 'fusion event' as a fusion present in a cell line. Thus, we identified 10,514 fusion transcripts, representing 8,354 gene fusion events and, because a small number of fusions are recurrent, 7,430 unique fusions ( Supplementary Table 2 ).
Next, we examined the number of fusion events that occurred in different cancer types.
Cell lines had a median of six fusion events and 26% of fusion events were predicted to be in-frame. Fusion numbers varied by cancer type (Fig. 1c) , with osteosarcoma and breast cancer having the most (median of 16 fusion events per cell line), and kidney cancers and B-lymphoblastic leukemia together with three non-cancerous immortalized human cell lines having the lowest median number of fusion events (median = 2). The prevalence of fusion events for each cancer type in our cell lines was slightly higher, but significantly correlated with the frequency reported from the analysis of 9,624 patient samples (p < 0.001, R 2 = 0.42; Supplementary Fig. 1 ), indicating cell lines reflect the frequency of fusions in tumours from different tissues 13 . We identified recurrent known oncogenic fusions events in our dataset, including BCR-ABL1 (n = 11), NPM1-ALK (n = 5), EWSR1-FLI1 (n = 24) and TMPRSS2-ERG (n = 2). Of note, only 431 of 7,430 (6%) fusions were recurrent, while the remaining were detected in only one cell line ( Fig. 1d ), indicating most fusions are rare.
Of the fusion events we identified, 11.1% have been reported previously in human tumor samples 13 and for 14.2% of the fusion events, at least one of the fused genes was found in the COSMIC Cancer Gene Census, representing a significant enrichment for cancer genes (odds ratio = 1.8 and p < 0.001, Fisher's test). TSGs were enriched as 5' end partner genes (odds ratio = 2.1 and p < 0.001, Fisher's test), while oncogenes were enriched as 3' or 5' genes (odds ratio = 2 and 1.8, respectively, p < 0.001, Fisher's test). We found known oncogenic fusions enriched in specific cancer types consistent with their pathognomonic nature, such as ABL1 -fusions in chronic myeloid leukemia (n = 9; p = < 0.001), EWSR1-FLI1 fusions in Ewing's sarcoma (n = 24; p = < 0.001) and FGFR3 fusions in bladder cancer (n = 3; p = < 0.001) ( Supplementary Fig. 1 ). In summary, using stringent criteria we built a comprehensive landscape of fusions in cancer cell lines, most of which occur at a low frequency, and reflect the prevalence and tissue specificity in tumor samples. 
Fusion transcripts impact gene expression
Fusions may result in altered expression of either or both of the fusion partner genes 13 .
To identify genes whose expression is altered when fused, we first aggregated fusion events that had a common gene partner at the 5' or the 3' end to increase sample size and statistical power. We then used a linear regression model to link expression with the presence of a fused gene, incorporating bias due to copy number alterations and cancer type. In total, we tested 902 genes (5' genes: 611 and 3' genes: 383) that involved 3,048 fusions. We identified 172 (19%) genes significantly associated with differential expression (5' genes: 54 (9%) and 3' genes: 118 (31%)) that encompassed 592 fusions. Of the significantly associated genes, 24 (14%) were known cancer drivers from the COSMIC census (2.5% of the total; Fig. 2a and Supplementary   Table 3 ). As expected, several TSG such as TP53 , APC and KDM6A were significantly associated with reduced expression (p < 0.001, Supplementary Fig. 1 ). In contrast, many known oncogenes fused at the 3' were overexpressed, including ALK , ERG , FL1 , MYC , MLL4 and ROS1 (p < 0.001, Supplementary Fig. 1 ).
Because most fusions are rare and therefore not suitable for linear regression modelling, we also annotated expression of genes involved in each fusion event (n = 8,354). We focused on 3' end genes with exceptionally high expression because overexpression of proto-oncogenes occuring as 3' partner genes is observed in several malignancies 13, 14 . We found that 25.6% (n = 2,145) of fusion events were coincident with high expression and did not co-occur with copy number amplification. Only 5.4% (1.4% of the total; n = 117) of these fusion events involve the overexpression of a driver gene ( Fig. 2b ) ( Supplementary Table 4 ). This analysis revealed that aberrant transcript expression of genes involved in gene fusions is a common event, but only a small subset of these fusions involve established driver oncogenes.
Novel contexts of chimeric transcripts were identified leading to overexpression of known cancer genes located the fusion 3' end, such as NUTM1 , RSPO2/3 and ROS1 (Fig. 2b ). In support of this observation, we validated by Sanger sequencing and fluorescent in situ hybridisation (FISH) a previously uncharacterized RWDD1-ROS1 fusion in the OCUB-M cell line, which is derived from a triple-negative breast cancer ( Supplementary Fig. 2 ). ROS1 is a receptor tyrosine kinase and gene rearrangements leading to ROS1 overexpression have been identified and validated as therapeutic biomarker of response to ROS1 kinase inhibitors in non-small cell lung cancer and, recently, in other cancer types ( Supplementary Fig. 2 ) 15 . The fusion retains the ROS1 protein kinase domain and OCUB-M cells display sensitivity to crizotinib and foretinib, two potent ROS1 inhibitors ( Supplementary Fig. 2 ) 16, 17 . Interestingly, in a dataset of 590 breast cancer patients, we identified a triple-negative and a HER2+ sample carrying in-frame fusions involving the ROS1 kinase domain 18 ( Supplementary Fig. 2 ), suggesting that a rare subset of breast cancer patient could be potentially eligible to targeted tyrosine kinase inhibitor-based therapies. Systematic analysis for fusion markers of drug response.
Fusion proteins can impact on clinical responses to therapy. Consequently, we reasoned that differential drug sensitivity in cell lines could be used to identify functional fusions, as well as opportunities for repurposing of existing drugs. We used an established statistical model 8, 19 to perform an analysis of variance (ANOVA) linking the 431 recurrent gene fusions (n ≥ 2 cell lines)
with 308,634 IC50 values for 409 anti-cancer drugs (334 unique compounds) screened across 982 of our cell lines as part GDSC project ( Fig. 3a , Supplementary Table 5 ). The compounds 9 assessed consisted of anti-cancer chemotherapeutics and molecularly targeted agents, including many which are FDA-approved (n = 46; Fig. 3a ) or in clinical development (n = 65).
This included data for 155 new compounds and a total of 212,774 previously unpublished IC50 values. Preliminary analyses indicated that mutations in cancer driver genes co-occurring with fusions in cell lines were frequent confounders when identifying fusion-specific associations. To control for this, we first identified associations between 717 cancer driver mutations and copy number alterations and drug sensitivity, then used them as a covariate in the ANOVA to identify fusion-specific associations (Supplementary Table 6 ). Adding the covariates resulted in 11 fusion associations falling below our threshold for statistical significance. For instance, the association of NKD1-ADCY7 with BRAF-inhibitor dabrafenib was explained by the presence of a BRAF mutation in one highly sensitive cell line ( Supplementary Fig 3) .
We identified 227 large-effect size associations (FDR < 25% and Glass Deltas > 1; the Glass Delta is a measure of effect size incorporating the standard deviation) between gene fusions and drug sensitivity ( Fig. 3b ; Supplementary Table 7 ). At the level of individual fusion events, 284 (21%) of 1,355 tested fusion events showed a significant association with a drug.
Most of the the strongest fusion-drug associations were well understood cases, such as sensitivity of ALK -fusion positive cell lines to ALK inhibitors, for example, alectinib, (FDR < 0.1%), and sensitivity of BCR-ABL1 translocation positive cells to ABL inhibitors, such as imatinib and nilotinib, (FDR < 0.1%) ( Fig. 3c ). We also identified associations with low frequency fusions, such as sensitivity to multiple EGFR inhibitors, such as cetuximab, in two CRTC1-MAML2 fusion positive cells (FDR < 0.1%), mediated as a result of paracrine induction of EGFR signaling 20 (Fig. 3c ). Following manual curation, most associations between fusions and drug sensitivity could be readily explained by known interactions (n = 66; 30%), mutations in secondary genes (n = 7; 3%), and fusions that were either not in-frame (n = 77; 34%) or not 10 seen in patient samples (n = 131; 57%). The remaining associations (n = 35; 15%) generally involve poorly described fusions present in 2 or 3 cell lines, making drug sensitivities difficult to interpret.
This analysis was limited in power by the small number of recurrent fusions genes in the dataset. Nonetheless, it suggests that besides well-established oncogenic fusions, there are few recurrent gene fusions that could be used as therapeutic biomarkers for repurposing of existing anti-cancer drugs. We did, however, observe potent drug sensitivity to particular drugs in individual cell lines with rare fusions. 6, 21 . We then mapped the coordinates of the sgRNAs targeting either of the fusion genes, and classified them as mapping or non-mapping sgRNAs, depending on whether they targeted the fusion transcript or not (Fig 4a) . We calculated a fusion essentiality score (FES) for each gene fusion transcript partner as the differential scaled fold-change between mapping and non-mapping guides, or, where a fusion transcript had no non-mapping guides, the value of non-mapping guides was set to zero.
We identified mapping sgRNA for 2,821 fusions transcripts, of which 129 fusion transcripts (5%) (representing 103 fusion events) were significantly associated with decreased cell fitness when targeted in at least one data set ( Fig. 4b , Supplementary Table 8 ). Using a gene-set enrichment analysis, we found an enrichment in significant FES for fusions transcripts in the COSMIC fusion database of driver oncogenic fusions (p < 0.001), which included well-known oncogenic fusions like EML4-ALK (FDR < 0.5%), EWSR1-FLI1 (FDR < 0.5%) and
KMT2A-MLLT3
(FDR < 0.5%) and TPM3-NTRK1 (FDR < 0.5%) (Fig 4b and c , Supplementary   Fig. 3 ). Among the most significant associations were YAP1-MAML2 fusions (FDR < 0.01%),
DDX6-FOXR1
(FDR < 0.5%) and PICALM-MLLT10 (FDR < 0.5%). Interestingly, there was no enrichment in significant FES for fusion transcripts that were: (i) previously reported in patient samples; (ii) fusion transcripts that are in-frame vs. not in-frame; (iii) fusion transcripts in amplified regions, which are associated with non-specific fitness effects in CRISPR screens; (iv) nor for fusion transcripts that involve genes in the COSMIC Census 22 . These results demonstrate the ability to identify functional fusion transcripts using CRISPR-Cas9 screening datasets, but that for most tested fusions, including those identified in patients and involving cancer driver genes, we did not detect evidence supporting a functional role for cancer cell fitness.
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Druggable RAF1 fusions in pancreatic adenocarcinoma cells
Rare RAF1 fusions have been reported in patient tumors [23] [24] [25] , and RAF fusions are biomarkers of response to MAPK pathway inhibition. We identified an in-frame ATG7-RAF1 fusion in PL18, a pancreatic adenocarcinoma cell line (Fig. 5a ). The fusion was confirmed by Sanger sequencing across the breakpoint and fluorescence in situ hybridization (FISH) ( Fig. 5b and Supplementary Fig. 4 ). The fusion removes the N-terminal regulatory regions but retains an intact RAF1 protein kinase domain, suggesting it results in constitutive kinase activation.
Only mapping sgRNAs targeting the portion of the two genes involved in the fusion were significantly depleted, resulting in a significant FES (Fig. 5c ). Moreover, of the 27 pancreatic cancer cell lines analysed by CRISPR screening, ATG7 fusion-targeting sgRNA were only depleted in PL18 cells (Fig. 5d ). Unlike >90% of pancreatic tumors and cell lines that have a ctivating mutations in KRAS 8, 26 , PL18 has a wild-type KRAS allele, but retained potent sensitivity to downstream MEK pathway inhibitors trametinib and PD0325901 ( Fig. 5e and Supplementary Figure 4 ). An ATG7-RAF1 rearrangement was previously reported in another KRAS-wt pancreatic cancer model 27 . Furthermore, we mined sequencing data for 126 pancreatic adenocarcinoma patient-derived xenograft (PDX) models and identified an additional KRAS wild-type tumor with a PDZRN3-RAF1 fusion which conserves the RAF1 kinase domain ( Supplementary Figure 4) . Our data support emerging evidence for rare recurrent and potentially therapeutically actionable RAF1 rearrangements in KRAS wild-type pancreatic cancer.
Druggable BRD4-NUTM1 fusion in lung cancer cells BRD4-NUTM1 fusions genetically define NUT midline carcinoma (NMC), a rare and aggressive neoplasm that usually arises in the midline of the body with marked sensitivity to BET bromodomain inhibitors (BETi) 28, 29 . We identified a novel in-frame BRD4-NUTM1 fusion in SBC-3, a small cell lung carcinoma (SCLC) cell line and confirmed the fusion by Sanger sequencing and FISH ( Fig. 5a and b, Supplementary Fig. 4 ). Based on CRISPR data on 206 cell lines screened at Sanger, NUTM1 -targeting guides were highly depleted only in SBC-3 cells, and the fusion was associated with a significant FES ( Fig. 5c and Supplementary Figure   4 ). Moreover, SBC-3 cells displayed marked sensitivity to four different BETi ( Fig. 5e and Supplementary Fig. 4 ). Unlike >95% of SCLC tumors and cell lines, SBC-3 cells do not have alterations in RB1 or TP53 , nor do they express SCLC-specific neuroendocrine markers such as CgA, NSE and synaptophysin ( Supplementary Figure 4) . The BRD4-NUTM1 fusion was specifically associated with high NUTM1 transcript expression in cell lines ( Fig. 2 and Supplementary Figure 4) . Therefore, we mined TCGA expression data for SCLC and non-SCLC (NSCLC) searching for samples displaying high NUTM1 mRNA levels. We identified a single NSCLC sample, displaying NUTM1 mRNA outlier expression ( Supplementary Figure 4) and carrying a NSD3-NUTM1 rearrangement 13 ( Supplementary Fig. 4 ), a chimeric oncoprotein recently identified in NMC patients and previously associated to BETi sensitivity 30 . NUT rearrangements were identified in rare subpopulation of SCLC and NSCLC patients 31, 32 and recent studies established that NUT -associated fusions can occurs in tumors outside the midline, such as soft tissue, brain, and kidney 33 . Our preclinical data suggest that NUTM1 fusions could represent an actionable driver event in lung cancer with immediate potential clinical implications.
Lack of pathway dependence in cells with canonical R-spondin fusions
Aberrant expression of RSPO2/3 fusion transcripts synergize with WNT-ligands to trigger WNT pathway activation in APC wild type colorectal cancer (CRC) 14 . WNT pathway blockade with porcupine inhibitors is effective in RSPO3 -rearranged CRC preclinical models 34, 35 and clinical trials in patients with RSPO2/3 -fusion positive tumors of any histological origin are ongoing ( NCT01351103) . Here, we detected and validated two unreported canonical R-spondin fusions in cell lines derived from biliary tract (EGI-1; PTPRK-RSPO3 fusion) and esophageal (ESO51; EIF3E-RSPO2 fusion) cancer by PCR and FISH ( Fig. 5a and Supplementary Fig. 5 ).
Aberrant expression of RSPO2/3 was detected in both cell lines ( Fig. 2b and Supplementary   Fig. 5 ). Similarly, through mining TCGA esophageal cancer data, we found that a tumor with 17 high RSPO3 expression (>95th percentile) was positive for a canonical RSPO3 fusion 13 ( Supplementary Fig. 5) . Surprisingly, sgRNA mapping to the fusion were not associated with significant FES, and EGI-1 and ESO51 were insensitive to WNT pathway blockade ( Fig. 5e and Supplementary Fig. 5 ). This was in contrast to SNU1411, a positive control CRC cell line model addicted to WNT-pathway activation by rearranged RSPO3 , which was sensitive to multiple porcupine inhibitors 36 (Fig. 5e and Supplementary Fig. 5 ) Recurrent YAP1-MAML2 fusions drive Hippo-pathway signalling in different tissue types
We next used our CRISPR screening data to investigate the function of poorly understood fusions. Recurrent YAP1-MAML2 fusions were identified in AM-38 (glioblastoma), ES-2 (ovarian carcinoma) and SAS (head and neck carcinoma) cell lines (Fig. 6a) . We validated the fusion events in all three cell lines by PCR, and interphase and fiber FISH ( Fig. 6b and Supplementary Fig. 6 ). YAP1-MAML2 fusions have been reported in nasopharyngeal carcinomas and in a sample from a patient with skin cancer 13, 37 , but not in the 3 tumour types reported here (Fig. 6a ). The fusion brings together exons 1-5 of YAP1 and exons 2-5 of MAML2 , a transcript structure that is conserved across all three cell lines and patient samples (Fig. 6c ).
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A functional role for YAP1-MAML2 fusions has not been previously been reported. We found that YAP1-MAML2 fusions were significantly associated with decreased cell fitness when targeted in the CRISPR screen ( Fig. 4b and 6d ). Furthermore, loss of fitness in response to MAML2 -depletion is unique to MAML2 -fused cell lines in the three cancer types where the fusion is observed (Fig. 6e ). YAP1 overexpression is linked with poor prognosis, chemoresistance and resistance to cell death in multiple solid tumors. YAP1 is a transcriptional co-activator of the Hippo pathway through binding with the TEAD1 transcription factor and MAML2 is a transcriptional co-activator involved in NOTCH signaling 38 . YAP1-MAML2 fuses the transcriptional activation domain of MAML2 with the TEAD-binding domain of YAP1. Intriguingly, ES-2 and AM-38, although not SAS, also showed essentiality for TEAD1 in the CRISPR-dropout screen (data not shown), suggesting that the fusion protein signals through TEAD1.
To further investigate fusion protein activity, we performed gene-set enrichment comparing the three YAP1-MAML2 fusion positive cell lines against all others. Of 189 pathways tested, the YAP1-conserved signature was the most significant hit (adjusted p < 0.001) (Fig. 6f ).
The same signature was highly enriched when ES-2 was compared against all other ovarian cancer cell lines and SAS against all other head and neck cell lines, while expression of prototypic tissue-specific oncogenic signatures, such as estrogen receptor signaling in ovary, were depleted ( Supplementary Fig. 6 ). In summary, we demonstrate that recurrent YAP1-MAML2 fusion are associated with increased YAP1 signaling and required for cell fitness.
Our results support targeting the Hippo-signalling cascade in YAP1-MAML2 fusion-positive tumours. We demonstrate that most fusions are rare events occurring in a small number of cell lines, and their frequency and distribution broadly matches what is observed in patient tumours.
In total, we tested 3,354 fusion events and found supporting evidence of a functional role for 23 368 (11.8%) by either CRISPR data (n = 103) or ANOVA analysis (n = 284)( Fig. 6g [41] [42] [43] . We provide specific and previously undescribed data on fusions involving RAF1 , ROS1 and BRD4 that suggest existing drugs could be repurposed for use in rare pancreatic, breast, and lung cancers. Further studies using tumour xenograft models would support the in vivo efficacy of these findings and could pave the way for their clinical application.
More broadly, these results support the use of validated oncogenic fusions as therapeutic biomarkers in diverse histologies, and the utility of basket trials for clinical development of drugs targeting fusion proteins irrespective of tumour type, such as the type used for the development Entrectinib in solid tumour with ALK , ROS1 and NTRK fusions 43 .
A notable exception in our analysis was the differential sensitivity to WNT-pathway inhibition of CRC versus biliary tract and esophageal cancer cell lines with canonical R-spondin fusions. This suggests that tissue context could impact the functional role of some fusions as has been observed for oncogenes (e.g. BRAF -mutated CRC 44 ), with implications for development of genotype-directed trials in multiple tissue histology. Further investigations are warranted to understand this difference, and drug combinations could be evaluated in these specific context to overcome resistance similar to what is in clinical development for BRAF -mutated CRC 44 .
We identified and functionally evaluated less well studied gene fusions, as exemplified by YAP1-MAML2 rearrangements, which are required for cell fitness in multiple histology and associated with increased YAP1 signaling. Given the emerging role of YAP1/TEAD1 and the Hippo pathway in cancer, there is interest in pharmacological inhibition of Hippo-signaling as an anticancer therapeutic strategy 45 . We provide preclinical evidence supporting inhibition of this signaling axis in YAP1-MAML2 fusion positive tumors, with could pave the way for clinical development in a rare but defined patient population.
Our analysis supports the use of functional perturbation studies in preclinical models as an unbiased platform to systematically assess the impact of fusions in cancer. Extending this approach to a larger set of cancer models that represents the histopathologic and genomic diversity of patient tumours could reveal additional new insights with clinical relevance. In conclusion, we find that most fusions are not functional, with important implication for the interpretation of tumour sequencing data. Nonetheless, we identified fusion gene drivers of carcinogenesis which could represent future targets for drug development and specific actionable leads with potential for immediate clinical development in defined fusion-positive patients.
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